论文部分内容阅读
目的:研究NJ001特异性抗原在胰腺癌患者组织中的表达情况,探讨其与临床病理特征之间的关系及预后价值。方法:采用免疫组织化学方法对89例胰腺癌组织、17例胰腺良性疾病组织中NJ001特异性抗原进行检测,用半定量评分法判定结果,同时结合患者的临床病例资料,使用χ2检验或Fisher确切概率法进行相关性分析。Kaplan-Meier生存曲线评价该抗原的表达情况对预后的影响。结果:免疫组织化学结果显示,NJ001特异性抗原在胰腺癌组织中表达高于胰腺良性疾病组织(77.5%vs17.6%,P<0.001)。进一步分析发现:低分化患者该抗原的阳性表达率高于高分化患者(83.0%vs 60.0%,P=0.027);且在肿瘤浸润程度深、存在淋巴转移的患者中该抗原的阳性表达率分别高于浸润程度低、无淋巴转移者(82.2%vs 53.3%,P=0.037;91.1%vs62.8%,P=0.002),差异有统计学意义。生存分析显示,该抗原表达阳性的患者的生存时间短于表达阴性的患者(P=0.036)。结论:NJ001特异性抗原的表达与胰腺癌的分化程度、浸润深度、淋巴结转移及预后密切相关,该抗原有望成为检测胰腺癌进展的新的标志物。
Objective: To investigate the expression of NJ001 specific antigen in pancreatic cancer tissues and to explore its relationship with clinicopathological features and its prognostic value. Methods: Immunohistochemical method was used to detect NJ001 specific antigen in 89 cases of pancreatic cancer tissues and 17 cases of benign pancreatic diseases. Semi-quantitative score method was used to determine the results. Combined with the clinical data of patients, using χ2 test or Fisher exact Probability method for correlation analysis. Kaplan-Meier survival curve to evaluate the expression of the antigen on the prognosis. Results: The results of immunohistochemistry showed that NJ001 specific antigen was higher in pancreatic cancer tissues than in benign pancreatic tissues (77.5% vs 17.6%, P <0.001). Further analysis showed that the positive expression rate of the antigen in poorly differentiated patients was higher than that in well-differentiated patients (83.0% vs 60.0%, P = 0.027). The positive rates of the antigen in patients with deep tumor infiltration and lymphatic metastasis were (82.2% vs 53.3%, P = 0.037; 91.1% vs62.8%, P = 0.002). The difference was statistically significant. Survival analysis showed that patients with positive antigen expression had a shorter survival time than patients with negative expression (P = 0.036). Conclusion: The expression of NJ001 specific antigen is closely related to the degree of differentiation, depth of invasion, lymph node metastasis and prognosis of pancreatic cancer. The antigen may be a new marker for detecting the progression of pancreatic cancer.